$135 Million is the total value of Opaleye Management Inc.'s 30 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 65.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RTRX | New | RETROPHIN INC | $24,448,000 | – | 1,153,230 | +100.0% | 18.06% | – |
| ARIA | ARIAD PHARMACEUTICALS INC | $13,460,000 | -99.9% | 1,670,000 | 0.0% | 9.94% | +6.8% | |
| CMRX | New | CHIMERIX INC | $12,242,000 | – | 536,000 | +100.0% | 9.04% | – |
| PCYC | Sell | PHARMACYCLICS INC | $11,525,000 | -99.9% | 115,000 | -4.2% | 8.51% | -16.3% |
| NSPR | Buy | INSPIREMD INC | $6,560,000 | -99.8% | 2,150,000 | +89.5% | 4.85% | +109.3% |
| OMER | Buy | OMEROS CORP | $6,036,000 | -99.9% | 500,100 | +8.7% | 4.46% | +12.3% |
| CEMP | Buy | CEMPRA INC | $5,544,000 | -99.9% | 480,000 | +31.5% | 4.10% | +9.9% |
| BINDQ | Buy | BIND THERAPEUTICS INC | $5,107,000 | -99.8% | 427,000 | +175.5% | 3.77% | +126.3% |
| P103PS | Sell | NPS PHARMACEUTICALS INC | $4,490,000 | -99.9% | 150,000 | -26.8% | 3.32% | -28.9% |
| GNMK | New | GENMARK DIAGNOSTICS INC | $4,324,000 | – | 435,000 | +100.0% | 3.19% | – |
| CSII | CARDIOVASCULAR SYS INC DEL | $4,292,000 | -99.9% | 135,000 | 0.0% | 3.17% | -9.4% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $4,116,000 | -99.9% | 167,600 | 0.0% | 3.04% | +35.9% | |
| FLDM | Sell | FLUIDIGM CORP DEL | $3,966,000 | -99.9% | 90,000 | -32.1% | 2.93% | -25.9% |
| BLRX | Buy | BIOLINERX LTDsponsored adr | $3,236,000 | -99.8% | 1,451,000 | +103.5% | 2.39% | +47.3% |
| CPRX | Buy | CATALYST PHARM PARTNERS INC | $3,116,000 | -99.9% | 1,378,584 | +1.8% | 2.30% | +11.0% |
| EPZM | New | EPIZYME INC | $2,630,000 | – | 115,500 | +100.0% | 1.94% | – |
| LGND | Sell | LIGAND PHARMACEUTICALS INC | $2,354,000 | -100.0% | 35,000 | -61.1% | 1.74% | -54.4% |
| GERN | Sell | GERON CORP | $2,299,000 | -100.0% | 1,100,000 | -58.3% | 1.70% | -83.6% |
| FLXN | New | FLEXION THERAPEUTICS INC | $2,229,000 | – | 135,500 | +100.0% | 1.65% | – |
| EVOK | New | EVOKE PHARMA INC | $1,956,000 | – | 233,400 | +100.0% | 1.44% | – |
| CELGZ | Sell | CELGENE CORPrights 12/31/2030 | $1,881,000 | -99.9% | 660,000 | -17.5% | 1.39% | -21.0% |
| TTPH | Buy | TETRAPHASE PHARMACEUTICALS I | $1,757,000 | -99.9% | 160,000 | +4.2% | 1.30% | -17.1% |
| KBIO | Buy | KALOBIOS PHARMACEUTICALS INC | $1,474,000 | -99.9% | 545,000 | +91.2% | 1.09% | +18.8% |
| ARRY | New | ARRAY BIOPHARMA INC | $1,434,000 | – | 305,000 | +100.0% | 1.06% | – |
| CDXS | New | CODEXIS INC | $1,425,000 | – | 698,300 | +100.0% | 1.05% | – |
| CPXX | Buy | CELATOR PHARMACEUTICALS INC | $1,031,000 | -99.9% | 325,000 | +4.8% | 0.76% | +1.1% |
| MGNX | New | MACROGENICS INC | $838,000 | – | 30,000 | +100.0% | 0.62% | – |
| AFFX | New | AFFYMETRIX INC | $713,000 | – | 100,000 | +100.0% | 0.53% | – |
| KIPS | New | KIPS BAY MED INC | $540,000 | – | 777,531 | +100.0% | 0.40% | – |
| SSH | Sell | SUNSHINE HEART INC | $350,000 | -100.0% | 60,000 | -85.9% | 0.26% | -92.0% |
| MDVN | Exit | MEDIVATION INC | $0 | – | -25,000 | -100.0% | -1.26% | – |
| INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -130,000 | -100.0% | -1.31% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS INC | $0 | – | -56,900 | -100.0% | -2.86% | – |
| GENTY | Exit | GENTIUM S P Asponsored adr | $0 | – | -505,000 | -100.0% | -22.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.